Biodexa Pharmaceuticals Plc
BDRXNasdaq
$2.13
0.0%Jul 17 close · end-of-day
Price
1Y↓ -94.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
No screener snapshot for this ticker.
Company profile
Midatech Pharma plc focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. MTX114, an immuno-suppressant for topical application in psoriasis, MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder.
- CEO
- Stephen A. Stamp
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Website
- midatechpharma.com
Earnings
No reported earnings periods on file.
Financial statements
No annual data.
No quarterly data.
Company news
Jun 30, 2026
- 20d agoResult of Annual General Meetingfinance.yahoo.com
- 20d agoEuropean Equities Traded in the US as American Depositary Receipts Rise in Tuesday Tradingfinance.yahoo.com
- 20d agoBiodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrantsfinance.yahoo.com
Jun 29, 2026
- 21d agoEuropean Equities Traded in the US as American Depositary Receipts Track Higher in Monday Tradingfinance.yahoo.com
- 21d agoBDRX: Expanding Phase 3 SERENTA Trial into Canada; 73 Patients Enrolled Thus Farfinance.yahoo.com
- 21d agoApproval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progressfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.